We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture IRC technology Atreca has an unparalleled insight into how cancer patients immun... Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture IRC technology Atreca has an unparalleled insight into how cancer patients immune responses can drive better clinical outcomes. Atreca was founded by scientists industry experts and investors who share the vision that unlocking the immune response of todays patients is the key to creating a new generation of therapies. Atreca is looking for talented entrepreneurial people who are dedicated to making a positive impact on human health. Show more
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities...
false 0001532346 0001532346 2024-03-08 2024-03-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
false 0001532346 0001532346 2023-12-31 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
false 0001532346 0001532346 2023-12-19 2023-12-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (βAtrecaβ) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery...
SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | -0.1119 | -42.726231386 | 0.2619 | 0.2849 | 0.15 | 621044 | 0.20822081 | CS |
12 | 0.0225 | 17.6470588235 | 0.1275 | 0.4448 | 0.1023 | 9925709 | 0.2746614 | CS |
26 | -0.142 | -48.6301369863 | 0.292 | 0.6562 | 0.1023 | 5596964 | 0.28094441 | CS |
52 | -1.09 | -87.9032258065 | 1.24 | 1.35 | 0.1023 | 2812529 | 0.29534609 | CS |
156 | -14.83 | -98.9986648865 | 14.98 | 15.55 | 0.1023 | 1290389 | 1.64901957 | CS |
260 | -19.75 | -99.2462311558 | 19.9 | 29.35 | 0.1023 | 877489 | 2.87223343 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions